Santaris Regains Ownership of Cancer Programs Licensed to Enzon | GenomeWeb

Santaris Pharma said this week that partner Enzon has returned the rights to all of the data and intellectual property related to the locked nucleic acid drugs the companies were developing under a long-term partnership in cancer.

Santaris said it will also receive an undisclosed amount of money as part of the arrangement, and did not provide reasons behind Enzon's decision. None of the products the companies were working on were microRNA-related.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.